Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Debio 1450 in Healthy Subjects
NCT02214433Phase 1Completed
- Sponsor
- Debiopharm
- Start
- Aug 2014
- Primary completion
- Feb 2015
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of afabicin in bacterial infection (11 arms), sponsored by Debiopharm. Primary endpoints: Number of participants with clinically significant change from baseline in safety parameters, Maximum observed plasma concentration and 6 more. Started Aug 2014; status: completed.
02
Drugs
afabicin
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT02214433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02214433.